Gamida Cell expects to achieve the following milestones this year: Present additional data from the Phase 1 study of NAM-NK in first half of 2019. Report early data from the Phase 1/2 study of NiCord in patients with severe aplastic anemia data in the first half of 2019. Complete patient enrollment in the Phase 3 study of NiCord in patients with high-risk hematologic malignancies in the second half of 2019.
https://thefly.com/landingPageNews.php?id=2844639
https://thefly.com/landingPageNews.php?id=2844639
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.